Novel, fully synthetic fluorocycline; exhibits potent in vitro activity against a broad spectrum of common clinically relevant Gram-positive and -negative aerobic and anaerobic bacteria

Potent in vitro activity against clinically relevant bacteria expressing certain tetracycline-, carbapenem-, extended-spectrum cephalosporin-, methicillin- and vancomycin- specific acquired resistance mechanisms and extended-spectrum β-lactamase producing Enterobacteriaceae

Noninferior efficacy to ertapenem and meropenem, with an acceptable tolerability profile in pivotal phase 3 trials